Ganciclovir prophylaxis to prevent CMV disease in kidney recipients undergoing anti- lymphocyte globulin treatment for acute rejection Michael J. Dickenmann, Kairat Kabulbayev, Jürg Steiger, Gieri Cathomas, Pierre Reusser, Michael Tamm Clinical Microbiology and Infection Volume 10, Issue 4, Pages 337-339 (April 2004) DOI: 10.1111/j.1198-743X.2004.00827.x Copyright © 2004 European Society of Clinical Infectious Diseases Terms and Conditions
Fig. 1 Cumulative number of patients developing CMV infection or CMV disease within 6 months of rejection therapy (51 patients at risk). Clinical Microbiology and Infection 2004 10, 337-339DOI: (10.1111/j.1198-743X.2004.00827.x) Copyright © 2004 European Society of Clinical Infectious Diseases Terms and Conditions